IGFBP3 and Obesity: IGFBP-3 further inhibits TNF-α, CRP and high glucose-induced NF-kβ activity in human aortic endothelial cells and subsequently suppresses monocyte adhesion; suggesting a therapeutic target for obesity-induced insulin resistance and for events occurring in the early stages of atherosclerosis [106].